美国前列腺癌分期与种族发病率的更新评估:多重插补联合年龄与延迟调整的新方法
该研究基于SEER-18数据库2004-2017年774 240例前列腺癌病例,采用多重插补和延迟调整方法评估美国前列腺癌分期与种族发病趋势。结果显示2011-2017年转移性前列腺癌发病率年百分比变化为5.5,非西班牙裔黑人发病率最高,非西班牙裔白人50-74岁转移性前列腺癌发病率2017年较2004年高56%。
要点
- 2011-2017年转移性前列腺癌发病率年百分比变化为5.5。
- 非西班牙裔黑人前列腺癌发病率最高,尤其是转移性疾病。
- 非西班牙裔白人50-74岁转移性前列腺癌2017年发病率较2004年高56%。
核心结论
- 转移性前列腺癌发病率在2011-2017年持续增加,且种族差异持续存在。
- 多重插补和延迟调整对于准确描述分期和种族特异性前列腺癌发病率至关重要。
研究设计与样本
- 基于SEER-18数据库的观察性研究,纳入2004-2017年诊断的774 240例前列腺癌病例。
- 对4.7%分期缺失的病例进行多重插补,并应用SEER延迟因子调整病例计数,生成20个插补数据集,采用Rubin规则汇总估计。
- 按种族和年龄组分层的总体及分期特异性发病率估计,使用Joinpoint软件识别时间变化趋势和年百分比变化。
主要发现
- 转移性前列腺癌发病率在2011-2017年增加,年百分比变化为5.5。
- 自2014年以来,局限性和区域性疾病发病率也出现增加。
- 非西班牙裔黑人男性发病率最高,尤其是转移性疾病。
- 非西班牙裔白人50-74岁男性转移性前列腺癌发病率近期加速上升,2017年发病率比2004年高56%。
- 未采用多重插补和延迟调整的率估计在定量和定性上均不同。
临床怎么用
- 临床和公共卫生监测中应采用多重插补和延迟调整方法以准确评估前列腺癌分期和种族特异性发病率趋势。
- 应关注转移性前列腺癌发病率的持续上升,尤其是非西班牙裔黑人及50-74岁非西班牙裔白人男性。
局限性
- 观察性研究无法确定前列腺癌发病率变化的因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the USA, it is unknown whether metastatic prostate cancer incidence has continued to increase and whether racial differences have persisted. OBJECTIVE: Combining multiple imputation with age and delay adjustment, we provide an up-to-date, comprehensive assessment of US prostate cancer incidence trends by stage and race. DESIGN, SETTING, AND PARTICIPANTS: From Surveillance Epidemiology and End Results (SEER)-18, 774 240 prostate cancer cases were diagnosed during 2004-2017. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multiple imputation assigned prostate cancer stage to the 4.7% of cases with missing stage, which varied by year and race-ethnicity. SEER delay factors adjusted case counts to anticipated future data corrections. Twenty datasets were imputed, and Rubin's rules were used for summary estimation. Overall and stage-specific rates were estimated and stratified by race and age group. Joinpoint software identified significant temporal changes and estimated annual percentage changes. We compared these estimates without multiple imputation and delay adjustment. RESULTS AND LIMITATIONS: Metastatic prostate cancer incidence increased during 2011-2017, with an annual percentage change of 5.5. This was followed by increases in localized and regional disease since 2014. Non-Hispanic black men continued to have the highest incidence, especially for metastatic disease. The increasing rate of metastatic prostate cancer in non-Hispanic white men aged 50-74 yr accelerated recently, and the incidence was 56% higher in 2017 than in 2004. Rates without multiple imputation and delay adjustment were quantitatively and qualitatively different. This observational study is unable to assign causes to observed changes in prostate cancer incidence. CONCLUSIONS: Multiple imputation and delay adjustment are essential for portraying accurately stage- and race-specific prostate cancer incidence as clinical practice evolves. PATIENT SUMMARY: In the USA, diagnosis of prostate cancer that has spread to distant sites (metastatic disease) continues to increase. Black men continue to have higher risks of being diagnosed with metastatic prostate cancer than other race-ethnicities.
引用
- Cook MB, Hurwitz LM, Geczik AM, et al. An Up-to-date Assessment of US Prostate Cancer Incidence Rates by Stage and Race: A Novel Approach Combining Multiple Imputation with Age and Delay Adjustment. Eur Urol. 2020. PMID: 33092896. doi:10.1016/j.eururo.2020.09.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。